- /
- Supported exchanges
- / US
- / SPRB.NASDAQ
Spruce Biosciences, Inc. Common Stock (SPRB NASDAQ) stock market data APIs
Spruce Biosciences, Inc. Common Stock Financial Data Overview
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Spruce Biosciences, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Spruce Biosciences, Inc. Common Stock data using free add-ons & libraries
Get Spruce Biosciences, Inc. Common Stock Fundamental Data
Spruce Biosciences, Inc. Common Stock Fundamental data includes:
- Net Revenue: 697 K
- EBITDA: -63 254 000
- Earnings Per Share: -33
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Spruce Biosciences, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-09
- EPS/Forecast: -5.76
Get Spruce Biosciences, Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spruce Biosciences, Inc. Common Stock News
New
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and deve...
Spruce Biosciences GAAP EPS of -$6.68
* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symb...
American Express, Biogen upgraded: Wall Street's top analyst calls
American Express, Biogen upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that...
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric, Palantir Technologies, Roku, and More
Quick Read A U.S.-Iran ceasefire deal sent the Nasdaq surging 3% to 26,683 and the Dow to a new all-time high at 51,671, while oil plunged 4%. UBS nearly doubled Dynatrace's (DT) price target to $60,...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.